Back to Search
Start Over
Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor trial in HR+/HER2- advanced breast cancer
- Source :
- Thomson Reuters ONE. March 19, 2014
- Publication Year :
- 2014
-
Abstract
- (Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor trial in HR+/HER2- advanced breast cancer . Processed and [...]
- Subjects :
- Thomson Reuters Corp. -- Product development
Novartis International AG -- Product development
Information services industry -- Product development
Angiogenesis inhibitors
Information services -- Product development
Breast cancer
Pharmaceutical industry -- Product development
Information services industry
Business, international
American Society of Clinical Oncology
Afinitor (Medication)
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Thomson Reuters ONE
- Publication Type :
- News
- Accession number :
- edsgcl.362055170